Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New nasal spray aims to zap migraine pain in 2 hours

NCT ID NCT06103734

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a nasal spray called zavegepant could relieve migraine pain within 2 hours. Adults with migraines for at least a year were to use the spray at home for up to 4 attacks. The study was withdrawn before enrolling participants, so no results are available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Expected to start

Sep 2025

An estimate. Start dates often move.

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participants aged 18 years or older. 2. Participants with minimum 1 year history of migraine with age onset before 50 years of age. Exclusion Criteria: 1. History of retinal migraine, basilar migraine or hemiplegic migraine. 2. History or current evidence of uncontrolled, unstable or recently diagnosed cardiovascular or cardiometabolic disease. 3. Major depressive disorder or anxiety disorder. 4. Acute or chronic pain syndromes. 5. Conditions that may affect the administration or absorption of the nasal product. 6. History of alcohol abuse and/or illicit drug. 7. Other social, medical, or psychiatric condition that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. 8. Current use of any prohibited concomitant medication(s) or participants unwilling/unable to use a permitted concomitant medication(s) 9. History of use of ergotamine medications or triptans on greater than/equal to 10 days per month on a regular basis for greater than/equal to 3 months. Or history of non-narcotic analgesic intake on greater than/equal to 15 days per month for greater than/equal to 3 months for other pain indications. 10. Participation in clinical trial with non-biological investigational agents or interventional treatments (last study visit occurring) within the 30 days prior to Baseline Visit. Participation in clinical trial with biological investigational agents (last study visit occurring) within 90 days prior to Baseline Visit. Participation in any other investigational clinical trial while participating in this clinical trial. 11. Previous participation in any zavegepant study within the last 2 years. 12. ANY of the following findings at the Screening Visit and laboratory tests as assessed by the study-specific laboratory: 1. Class 2 or Class 3 obesity, defined as body mass index \>35 kg/m2. 2. Estimated Globular Filtration Rate \<30 mL/min/1.73 m2. 3. Total bilirubin ≥1.5 × upper limit of normal. 4. Liver transaminases ≥2.0 × upper limit of normal . 5. Neutrophil count ≤1000/μL (or equivalent).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Migraine are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.